Abstract | PURPOSE: MATERIALS AND METHODS: This investigation was approved by the animal care committee. Sixty nude rats with subcutaneously implanted HNSCC xenografts (six per group) were treated with (a) RF ablation (70 °C for 5 minutes), (b) PEGylated liposomes, (c) liposomal doxorubicin, (d) (186)Re-PEGylated liposomes (1295 MBq/kg), (e) (186)Re-liposomal doxorubicin (555 MBq/kg), (f) PEGylated liposomes plus RF ablation, (g) liposomal doxorubicin plus RF ablation, (h) (186)Re-PEGylated liposomes plus RF ablation, or (i) (186)Re-liposomal doxorubicin plus RF ablation. Six rats did not receive any treatment (control group). Tumor uptake in (186)Re therapy groups was monitored with small-animal single photon emission computed tomography for 5 days. Therapeutic efficacy was monitored for 6 weeks with measurement of tumor volume, calculation of the percentage injected dose of fluorine 18 fluorodeoxyglucose (FDG) in tumor from small-animal positron emission tomography (PET) images, and determination of viable tumor volume at histopathologic examination. Significant differences between groups were determined with analysis of variance. RESULTS: The average tumor volume (± standard deviation) on the day of therapy was 1.32 cm(3) ± 0.17. At 6 weeks after therapy, control of tumor growth was better with (186)Re-liposomal doxorubicin than with liposomal doxorubicin alone ( tumor volume, 2.26 cm(3) ± 0.89 vs 5.43 cm(3) ± 0.93, respectively; P < .01). The use of RF ablation with liposomal doxorubicin and (186)Re-liposomal doxorubicin further improved tumor control ( tumor volume, 2.05 cm(3) ± 1.36 and 1.49 cm(3) ± 1.47, respectively). The tumor growth trend correlated with change in percentage of injected dose of FDG in tumor for all groups (R(2) = 0.85, P < .001). Viable tumor volume was significantly decreased in the group treated with (186)Re-liposomal doxorubicin plus RF ablation (0.54 cm(3) ± 0.38; P < .001 vs all groups except (186)Re- liposomal doxorubicin alone). CONCLUSION:
|
Authors | Anuradha Soundararajan, Gerald D Dodd 3rd, Ande Bao, William T Phillips, Linda M McManus, Thomas J Prihoda, Beth A Goins |
Journal | Radiology
(Radiology)
Vol. 261
Issue 3
Pg. 813-23
(Dec 2011)
ISSN: 1527-1315 [Electronic] United States |
PMID | 22025735
(Publication Type: Journal Article)
|
Copyright | © RSNA, 2011. |
Chemical References |
- Antibiotics, Antineoplastic
- Liposomes
- Radiopharmaceuticals
- Rhenium
- Doxorubicin
|
Topics |
- Analysis of Variance
- Animals
- Antibiotics, Antineoplastic
(administration & dosage, pharmacokinetics, pharmacology)
- Carcinoma, Squamous Cell
(diagnostic imaging, therapy)
- Catheter Ablation
- Chemotherapy, Adjuvant
- Combined Modality Therapy
- Disease Models, Animal
- Doxorubicin
(administration & dosage, pharmacokinetics, pharmacology)
- Drug Synergism
- Head and Neck Neoplasms
(diagnostic imaging, therapy)
- Isotope Labeling
- Liposomes
- Nuclear Medicine
(methods)
- Radionuclide Imaging
- Radiopharmaceuticals
(administration & dosage, pharmacokinetics, pharmacology)
- Random Allocation
- Rats
- Rats, Nude
- Rhenium
(administration & dosage, pharmacokinetics, pharmacology)
- Transplantation, Heterologous
|